Key clinical point:
Major finding: The area under the receiver operating characteristic curve was 74.6% when creatinine clearance was added to the standard model for assessing TLS risk, compared with 65% for the standard approach.
Study details: A retrospective cohort study of 339 CLL patients.
Disclosures: Dr. Mato has received grant support, consulting fees, and/or fees for serving on a data and safety monitoring board or advisory board from AbbVie, AstraZeneca, Celgene, Janssen, TG Therapeutics, Pharmacyclics, Loxo, Sunesis, prIME Oncology, Pfizer, Johnson & Johnson, and Regeneron.
Mato A et al. iwCLL 2019, Abstract 2008.